Your session is about to expire
← Back to Search
Device
tDCS Brain-Stimulation for Depression
N/A
Recruiting
Led By Mayank A Jog, PhD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within the 2.5 hour fmri session
Awards & highlights
Study Summary
This trial is testing a low-cost, non-medicinal treatment for depression using MRI scans to track brain activity. Eligible patients aged 20-55 will receive $150 + parking after completing two in-person visits.
Who is the study for?
This trial is for adults aged 20-55 with depression who can consent, are either treatment-naive or on a stable antidepressant regimen without changes in the past 6 weeks. They must live near UCLA and have moderate depression scores. Excluded are pregnant individuals, non-English speakers, those with skin conditions affecting electrode placement, metal implants, severe depression, recent psychotherapy or neuromodulation therapy.Check my eligibility
What is being tested?
The study tests tDCS brain stimulation's effect on depression by placing electrodes on the scalp to alter neuron activity. MRI scans will monitor these effects during sessions over two weeks. Participants may receive real or sham tDCS and might perform cognitive tasks during MRI to see how this technique could be tailored for treating depression.See study design
What are the potential side effects?
tDCS side effects may include mild discomfort at the electrode site, itching or tingling during stimulation, fatigue, headache after treatment ends. Serious side effects are rare but can involve mania in bipolar patients (excluded from this trial) or seizures if protocols aren't followed.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ within the 2.5 hour fmri session
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within the 2.5 hour fmri session
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Activity changes in the dorso-fronto-limbic brain network
Secondary outcome measures
Limbic System
Trial Design
4Treatment groups
Experimental Treatment
Group I: Right DLPFC tDCS + taskExperimental Treatment2 Interventions
Participants randomized to this arm will receive tDCS at the right DLPFC brain region. Additionally, participants will be asked to perform a mental task (2-back working memory) at the same time.
Group II: Right DLPFC tDCSExperimental Treatment1 Intervention
Participants randomized to this arm will receive tDCS at the right DLPFC brain region.
Group III: Left DLPFC tDCS + taskExperimental Treatment2 Interventions
Participants randomized to this arm will receive tDCS at the left DLPFC brain region. Additionally, participants will be asked to perform a mental task (2-back working memory) at the same time.
Group IV: Left DLPFC tDCSExperimental Treatment1 Intervention
Participants randomized to this arm will receive tDCS at the left DLPFC brain region.
Find a Location
Who is running the clinical trial?
University of California, Los AngelesLead Sponsor
1,530 Previous Clinical Trials
10,278,058 Total Patients Enrolled
101 Trials studying Depression
48,299 Patients Enrolled for Depression
National Institute of Mental Health (NIMH)NIH
2,784 Previous Clinical Trials
2,689,131 Total Patients Enrolled
666 Trials studying Depression
251,440 Patients Enrolled for Depression
Mayank A Jog, PhDPrincipal InvestigatorUniversity of California Los Angeles (UCLA)
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I cannot stop taking my benzodiazepine medication for 2 weeks.My gender does not affect my eligibility.I have depression linked to my serious health condition.I understand the information given to me and can make decisions about my health care.I haven't changed my antidepressant medication in the last 6 weeks.I do not have skin conditions or treatments that cause irritation.I haven't had any brain stimulation treatments in the last 3 months.I do not have Bipolar I disorder.I am between 20 and 55 years old.I speak English fluently.I have a brain condition like a recent stroke or injury.I am currently taking medication that affects brain activity.I am currently undergoing psychotherapy.I have used anticonvulsants, lithium, or psychostimulants in the past month.My depression is moderate, possibly with anxiety.I don't have conditions that prevent scanning, like metal implants or severe claustrophobia.I have severe depression that hasn't improved with at least 2 treatments.I haven't changed my antidepressant medication in the last 6 weeks.I have been diagnosed with schizophrenia or dementia.My depression is moderate, possibly with anxiety.
Research Study Groups:
This trial has the following groups:- Group 1: Right DLPFC tDCS + task
- Group 2: Left DLPFC tDCS
- Group 3: Left DLPFC tDCS + task
- Group 4: Right DLPFC tDCS
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Depression Patient Testimony for trial: Trial Name: NCT05598034 — N/A
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does the research encompass participants of 40 years and older?
"This clinical trial is seeking participants aged between 20 and 55 years old. There are 193 studies targeting younger demographics, while 968 trials are dedicated to those over 65."
Answered by AI
What is the scope of individuals participating in this investigation?
"Affirmative. Clinicaltrials.gov data suggests that this trial is actively seeking out participants, which was initially posted on October 20th 2022 and last updated just a few days ago on October 25th 2022. A total of 144 patients are required from 1 medical centre in order to complete the study."
Answered by AI
Are participants still being enrolled in this trial?
"Clinicaltrials.gov reports that this trial has opened its recruitment process, with the first posting taking place on October 20th 2022 and a later edit occurring five days after."
Answered by AI
Who is admissible to participate in this medical investigation?
"This clinical trial is currently seeking 144 volunteers who are ages 20 to 55 and have been diagnosed with major depressive disorder (MDD). Candidates must meet the following requirements: a Hamilton Rating Scale for Depression score of 17 or higher but below 24, any gender or race/ethnicity, no change in treatment 6-weeks prior to enrollment, proximity to UCLA, and ability to provide informed consent."
Answered by AI
Who else is applying?
What state do they live in?
California
What site did they apply to?
University of California Los Angeles (UCLA)
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
2
Why did patients apply to this trial?
I take Lexapro for depression but sometimes still experience symptoms of depression. I'm curious if this will help.
PatientReceived no prior treatments
What questions have other patients asked about this trial?
How long are the sessions?
PatientReceived no prior treatments
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger